Privacy Policy
Start Here
Research
IPO & Public Offerings
Economy & Macro
Latest
Stock Market
Market Education
Energy & Commodities
Capital Markets
Federal Reserve & Rates
About
Contact

GLP-1 obesity

GLP-1 Startup Kailera Leads Biotech IPO Revival With $625M Deal

September 12, 2026May 3, 2026 by Bruno M.

Kailera Therapeutics’ $625M GLP-1 IPO anchors a Q2 2026 healthcare listing wave, with Hemab Therapeutics, Avalyn Pharma, and peers all jumping 52-89% from their offer prices.

Categories Stock Market Tags biotech IPO, capital markets, GLP-1 obesity, ipo market 2026, kailera therapeutics

Search

Explore ECMSource

New here? Begin with our guide to the site, then explore the subjects that match what you want to understand.

Start Here
Market Education
Stock Market
Capital Markets
Federal Reserve & Rates

Subscribe to Our Newsletter

Please leave this field empty

Oh hi there 👋
It’s nice to meet you.

Sign up to receive awesome content in your inbox, every month.

We don’t spam! Read our privacy policy for more info.

Check your inbox or spam folder to confirm your subscription.

Privacy Policy
Editorial Policy
Corrections Policy
Financial Disclaimer
Contact
About Bruno M.
Investor Tools